PRESSEPORTAL Presseportal Logo
All Stories
Follow
Subscribe to Stada Arzneimittel

10.12.2020 – 13:56

Stada Arzneimittel

STADA signs agreement to commercialize Rupafin® (rupatadine) in the MENA region

One document

STADA signs agreement to commercialize Rupafin® (rupatadine) in the MENA region

  • STADA secures license to market Rupafin® (rupatadine), a potent, EMA-approved second-generation antihistamine, in 10 Middle East-North Africa countries.
  • Mohamad Abdallah, Managing Director of STADA MENA, commented: "Rupafin® is an additional unique asset to our specialty pharmaceuticals portfolio in the MENA region. We will leverage our internal capabilities and STADA infrastructure in building this prominent brand."
  • According to David Perdigó, B2B Director, at Uriach: "We see STADA's experience in the MENA region as one of the key factors to achieve a Rupafin® leading position in the MENA region markets and to maximize the access to this modern, new-generation antihistamine researched and developed by Uriach."

Bad Vilbel, Germany; Barcelona, Spain; December 10, 2020 - STADA Arzneimittel and Uriach have today announced a commercial licensing agreement for Rupafin® (rupatadine) with the STADA Arzneimittel AG's subsidiary in the United Arab Emirates named STADA MENA DWC-LLC (herein together referred to as "STADA") in Bahrain, Jordan, Kuwait, Lebanon, Morocco, Oman, Qatar, Saudi Arabia, Tunisia and United Arab Emirates (UAE).

Under the terms of the license and commercialization agreement, Uriach will receive a non-disclosed upfront payment and will be eligible for additional commercialization payments. Uriach will retain exclusive production rights of Rupafin® and will sell the product to STADA for its clinical and commercial use on an exclusive basis in the 10 MENA markets.

Rupafin® is currently registered in some MENA countries for the treatment of allergic rhinitis and urticaria.

Mohamad Abdallah, Managing Director of STADA MENA, commented: "The Rupafin® agreement with Uriach will expand our specialty footprint. Besides our existing pain management, oncology and Parkinson's portfolio, we will be commercializing Rupafin® in both its tablet and pediatric oral solution forms.

This reinforces STADA's position as a go-to-partner for specialty pharmaceuticals, as well as for generics and consumer healthcare products."

According to David Perdigó, B2B Director, at Uriach: "This new agreement with STADA will give us the opportunity to bring Rupafin®, one of Uriach's star products, to the MENA region. The product launch will start in Saudi Arabia, the biggest market in the Middle East, and will be followed by two other important territories: United Arab Emirates and Kuwait.

This agreement strengthens the expansion of rupatadine in Asia, being already present in Japan and in several APAC territories."

Legal disclaimer

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide.

About Uriach

Uriach is a family-run pharmaceutical company with two main business areas: Consumer Healthcare (OTC and Natural Care) and Business to Business (including NCEs, Generics and Contract Manufacturing). Present in Spain, Italy and Portugal, Uriach is currently in a period of international expansion with its products being sold in more than 70 countries. Founded in 1838, the company has always maintained a profitable, sustainable business model. Uriach currently employs 1,000 staff at two chemical and pharmaceutical production plants in the Barcelona area in which it produces its own products and also manufactures for third parties. Uriach's turnover in the 2019 financial year was 228 million euro, of which 60% sales were outside the domestic market.

About Rupafin®

Rupafin® (Rupatadine) is an EMA approved potent second generation antihistamine, indicated for allergic rhinitis and urticaria. Its favorable efficacy/safety profile and availability in two dosage forms, tablets and pediatric oral solution, enables it to present a unique non-sedating treatment for both adults and children above two years of age.

STADA information for journalists :

STADA Arzneimittel AG / Media Relations
Stadastrasse 2-18 / 61118 Bad Vilbel / Germany 
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215
E-Mail: press@stada.de 

Or visit us on the Internet at www.stada.com/press

STADA information for capital market participants:

STADA Arzneimittel AG / Investor & Creditor Relations
Stadastrasse 2-18 / 61118 Bad Vilbel - Germany
Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215
E-mail: ir@stada.de 

Or visit us on the Internet at www.stada.com/investor-relations

Uriach Media Contact

Belén Badia, Director of Communications

belen.badia@uriach.com

+34 938 630 13

+34 619 688 199

Oriol Giménez, Communications Manager

oriol.gimenez@uriach.com

+34 938 630 187

+34 635 565 045